Janssen and Pharmacyclics receive FDA approval for Imbruvica to treat WM

Janssen Biotech and Pharmacyclics have received approval from the US Food and Drug Administration (FDA) for Imbruvica (ibrutinib) capsules as the first therapy indicated specifically for patients with Waldenström's macroglobulinemia (WM), a rare, ind…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news